Navigation Links
Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment
Date:10/28/2009

ALEXANDRIA, Va., and BOSTON, Oct. 28 /PRNewswire/ -- The final results of the PROVE3 study will be presented at this year's annual meeting of the American Association for the Study of Liver Diseases. This phase 2 study was of telaprevir compared to a combination therapy of peginterferon alfa-2a and ribavirin. It intended to measure the 6 month and also 1-year durability of sustained viral response in genotype 1 patients with HCV who failed prior treatment with pegylated interferon and ribavirin.

According to John McHutchison, MD, principal investigator for this study, "This was the first large scale study performed in nonresponders to our current standard of care, which evaluated retreating these patients with the addition of an HCV-specific protease inhibitor. Its importance is, therefore, the proof of principle that adding this potent direct anti-viral allowed us to cure approximately 50 percent of this patient population who have failed therapy and for which no other options currently exists."

The study included 453 patients, and the SVR rates in all treatment groups who received the telaprevir-based therapy were significantly higher than those who received peginterferon alfa-2a and ribavirin. All patients who received telaprevir and achieved virologic response maintained it for 48 weeks after the end of the treatment.

The drug in this nonresponder setting is currently undergoing phase 3 large-scale registration trials to confirm and further elucidate the findings of this current phase 2 study. "To sit across the desk from our hepatitis C patients and tell those that have not responded that with this retreatment strategy they have a 50 percent chance of being cured will be a huge message for patients and providers if confirmed in larger phase 3 clinical trials," concluded Dr. McHutchison.

Abstract title:

PROVE3 final results and 1-year durability of SVR with Telaprevir-based regimen in hepati
'/>"/>

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
3. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
4. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
5. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
6. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
7. Patients Receiving High Radiation at Cedars Sinai File Class Action Lawsuit
8. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
9. Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
10. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
11. EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimers Disease Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
(Date:1/22/2015)... AMGN ) today announced that it will report its ... 27, 2015, after the close of the U.S. financial markets. The ... community at 2 p.m. PT. Participating in the call from Amgen ... officer, and other members of Amgen,s senior management team. ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced ... by Product, Application, Technology, End User - Global Forecast ... The infectious disease diagnostics market is expected to ... by 2019 from $12,422.8 million in 2014. Increase in ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 22, 2015 As interest in the value ... gains momentum worldwide, Rev. Eric J. Hall , president ... (HCCN), will be the keynote speaker on January 27 ... public health system. , The conference, “Hope and Resilience: Innovative ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... Henry M. Jackson Foundation for the Advancement of Military ... of the Health Sciences doctoral students to receive fellowships ... 1988, is comprised of two Henry M. Jackson Fellowships ... a stipend and travel support. Kathleen Jones, a ...
... and the Food and Drug Administration (FDA) are ... vision-related patient-reported outcomes might be used to improve ... are being incorporated more frequently into randomized clinical ... that such patient-reported outcomes are key to providing ...
... TRAVERSE CITY, Mich., Aug. 25 Versus Technology, Inc. ... fiscal quarter ended July 31, 2009, a 1.8% decrease compared to ... Revenues for the nine months ended July 31, 2009, were ... 2008, a 3.0% decrease. Versus, quarterly revenues can vary significantly ...
... , , , , ... Judd is speaking up for those struggling with chronic pain -- a ... combined. Judd is lending her voice to the national education program ... instpain.com ) to raise awareness about the urgent need to ...
... ... Product, the New Personal Germ Protection Spray , ... Mount Kisco, NY (PRWEB) August 25, 2009 -- ... agency specializing in national brand OTC health and beauty products, recently signed an agreement ...
... , , CARROLLTON, Ga., Aug. ... Prime Enterprise(TM) benefits Health Systems, Independent Physician ... Centers (ASCs) and other organizations seeking centralized management of practice, ... User rights management enables enterprise users to set security and ...
Cached Medicine News:Health News:Henry M. Jackson Foundation names fellowship award winners 2Health News:Versus Technology Announces Third Quarter Results 2Health News:Versus Technology Announces Third Quarter Results 3Health News:Versus Technology Announces Third Quarter Results 4Health News:Versus Technology Announces Third Quarter Results 5Health News:Versus Technology Announces Third Quarter Results 6Health News:Versus Technology Announces Third Quarter Results 7Health News:Country Legend Naomi Judd Joins 'Partners Against Pain' 2Health News:Country Legend Naomi Judd Joins 'Partners Against Pain' 3Health News:Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals 2Health News:Greenway Medical Technologies' PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers 2Health News:Greenway Medical Technologies' PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers 3
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... Automation, Inc.. (DAI) Measles IgG Enzyme-Linked Immunosorbent ... and quantitative determination of IgG antibody to ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
... osmolality at room temperature with the sample ... are cryoscopic artifacts due to high viscosity, ... with freezing point determinations. The superbly accurate ... osmometer has a much broader range of ...
Medicine Products: